瑞武美尼抑制menin治疗NPM1突变复发或难治性急性髓系白血病:AUGMENT-101研究
AUGMENT-101研究2期部分纳入84例接受过至少1剂瑞武美尼的复发或难治性NPM1突变急性髓系白血病患者,主要疗效可评估人群为64例成人患者,完全缓解或完全缓解伴部分血液学恢复率为23.4%(单侧P=.0014),总缓解率为46.9%,中位缓解持续时间4.7个月,安全性特征与既往报告一致。
要点
- 瑞武美尼在经多线治疗的NPM1突变复发或难治性急性髓系白血病中完全缓解或完全缓解伴部分血液学恢复率为23.4%。
- 总缓解率为46.9%,中位完全缓解或完全缓解伴部分血液学恢复持续时间为4.7个月。
- 30例缓解者中5例(16.7%)接受造血干细胞移植,治疗相关不良事件导致4例(4.8%)停药。
核心结论
- 瑞武美尼在经多线治疗的老年NPM1突变复发或难治性急性髓系白血病人群中显示出有临床意义的缓解,包括使患者得以接受造血干细胞移植的缓解。
- 瑞武美尼的安全性特征与既往报告结果一致。
研究设计与样本
- AUGMENT-101研究2期部分,纳入复发或难治性NPM1突变急性髓系白血病患者。
- 患者接受瑞武美尼联合或不联合强效CYP3A4抑制剂,每12小时一次,28天为一周期。
- 截至2024年9月18日,84例患者接受至少1剂瑞武美尼;中位年龄63岁,1例年龄小于18岁。
- 主要分析方案定义的疗效可评估人群为64例成人患者,其中既往接受至少3线治疗者占35.9%,既往接受维奈克拉者占75.0%。
- 主要终点为完全缓解或完全缓解伴部分血液学恢复率、安全性和耐受性;次要终点包括总缓解率和缓解持续时间。
主要发现
- 完全缓解或完全缓解伴部分血液学恢复率为23.4%(单侧P=.0014)。
- 总缓解率为46.9%。
- 完全缓解或完全缓解伴部分血液学恢复的中位持续时间为4.7个月。
- 30例缓解者中5例(16.7%)接受造血干细胞移植,其中3例在移植后恢复瑞武美尼治疗。
- 治疗相关不良事件导致4例患者(4.8%)停止治疗。
关键数值与推荐
- 完全缓解或完全缓解伴部分血液学恢复率23.4%(单侧P=.0014),总缓解率46.9%。
- 完全缓解或完全缓解伴部分血液学恢复的中位持续时间4.7个月。
- 30例缓解者中5例(16.7%)接受造血干细胞移植。
- 治疗相关不良事件导致停药4例(4.8%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The prognosis for relapsed or refractory (R/R) nucleophosmin 1-mutated (NPM1m) acute myeloid leukemia (AML) is poor and represents an urgent unmet medical need. Revumenib, a potent, selective menin inhibitor, was recently approved for the treatment of R/R acute leukemia with a KMT2A translocation in patients aged ≥1 year based on results from the phase 1/2 AUGMENT-101 study. Here, we present results from patients with R/R NPM1m AML enrolled in the phase 2 portion of AUGMENT-101. Enrolled patients received revumenib with or without a strong CYP3A4 inhibitor every 12 hours in 28-day cycles. Primary end points were rate of complete remission (CR) or CR with partial hematologic recovery (CRh; CR + CRh), safety, and tolerability. Secondary end points included overall response rate (ORR) and duration of response. As of 18 September 2024, 84 patients received ≥1 dose of revumenib. Median age was 63 years; 1 patient was aged <18 years. The protocol-defined, efficacy-evaluable population for the primary analysis included 64 adult patients (≥3 previous lines of therapy, 35.9%; previous venetoclax, 75.0%). The CR + CRh rate was 23.4% (1-sided P = .0014); the ORR was 46.9%. Median duration of CR + CRh was 4.7 months. Of 30 responders, 5 (16.7%) proceeded to hematopoietic stem cell transplant (HSCT) and 3 resumed revumenib after HSCT. Treatment-related adverse events led to treatment discontinuation in 4 patients (4.8%). Revumenib demonstrated clinically meaningful responses in this heavily pretreated, older population with NPM1m AML, including remissions that enabled HSCT. The safety profile of revumenib was consistent with previously reported results. This trial was registered at www.clinicaltrials.gov as #NCT04065399.
引用
- Arellano ML, Thirman MJ, DiPersio JF, et al. Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study. Blood. 2025. PMID: 40332046. doi:10.1182/blood.2025028357
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。